Immunic, Inc. Common Stock (IMUX) Stock Price
IMUXStock
$15.40+77.01%52W
Market Cap$210.12M
P/E—
PEG Ratio—
Div yield—
Beta1.40
IMUX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)59.56%
Price vs S&P 500 (4W)7.68%
VGM Score63.24
IMUX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$1.17 | -$0.80 | +31.33%(+$0.37) | |
| Q1 2026 | -$0.96 | -$1.08 | -12.84%(-$0.12) | |
| Q4 2025 | -$1.11 | -$0.70 | +37.00%(+$0.41) | |
| Q3 2025 | -$1.90 | -$1.30 | +31.58%(+$0.60) | |
| Q2 2025 | -$1.58 | -$2.00 | -26.32%(-$0.42) |
IMUX Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.36
4.38
4.38
4.38
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IMUXImmunic, Inc. Common Stock | — | — | B | $15.40 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Immunic, Inc. Common Stock
Immunic is a clinical-stage biopharmaceutical company developing selective oral therapies for chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, multiple sclerosis, and psoriasis. The company's pipeline includes three lead candidates: IMU-838 (immune cell metabolism inhibitor), IMU-935 (RORγt pathway modulator), and IMU-856 (intestinal barrier restoration). These therapies target large patient populations with significant unmet treatment needs.